Suppliers / KinOmega Biopharm

KinOmega Biopharm

China Updated 9 July 2026

KinOmega Biopharm is an API manufacturer based in China. It holds 3 active US drug master files and 3 valid CEPs across a filed portfolio of 4 molecules. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 24 January 2025 as VAI.

3
active US DMFs
3
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 24 January 2025 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Deyang City, China Not on file
China, China 3009754809

What they file, and where

Molecule Regulators Docs
Omega-3-Acid Ethyl Esters 90 EDQM 3
Icosapent US FDA 1
Icosapent Ethyl US FDA 1
Omega-3-Acid Ethyl Esters US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MFDS (Korea) None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. KinOmega Biopharm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 24 January 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates